Global R&D Pipeline
My Favorite
Hot Targets:
HER3
Back
Total number of drugs
141
Phase II and later clinical stages
9.9%
Involving companies
167
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patritumab Deruxtecan | Patritumab Deruxtecan | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | HER3 antagonists TOP1 inhibitors | Daiichi Sankyo Co., Ltd. | Merck Sharp & Dohme LLC Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. Institut Gustave Roussy EURL Merck Sharp & Dohme Corp. AstraZeneca PLC | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（United States） Priority Review（United States） | Patritumab | MC-GGFG | DXd | 8 | Patritumab Deruxtecan | IgG1 - kappa | cysteinyl | detail > | |
| Zenocutuzumab-zbco | Zenocutuzumab-zbco | Bispecific antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases | HER2 antagonists HER3 antagonists | Merus NV | Merus NV | Approved | Pending (in IND Approval) | United States | 2024-12-04 | - | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（United States） Priority Review（United States） | - | - | - | - | Zenocutuzumab-zbco | - | - | detail > | |
| Nezutatug | Nezutatug | Monoclonal antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | HER3 antagonists | Hummingbird Bioscience Pte Ltd. | Hummingbird Bioscience Pte Ltd. Cancer Research UK GenesisCare | Phase 1/2 | - | - | - | - | - | - | - | - | - | Nezutatug | - | - | detail > | |
| PM1300 | PM1300 | Antibody drug conjugate (ADC) | Neoplasms | EGFR antagonists HER3 antagonists | Biotheus, Inc. | Biotheus, Inc. BioNTech SE | Phase 1/2 | Phase 1/2 | - | - | - | - | - | Cleavable linker | - | - | PM1300 | - | - | detail > | |
| DB-1418 | DB-1418 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | EGFR antagonists HER3 antagonists | Duality Biologics (Suzhou) Co., Ltd. | Avenzo Therapeutics, Inc. Duality Biologics (Suzhou) Co., Ltd. | Phase 1/2 | IND Approval | - | - | - | - | - | - | - | 6 | DB-1418 | - | - | detail > | |
| Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Shenzhen Salubris Pharmaceuticals Co., Ltd.) | Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Shenzhen Salubris Pharmaceuticals Co., Ltd.) | Antibody fusion proteins | Cardiovascular Diseases Respiratory Diseases Other Diseases Nervous System Diseases Endocrinology and Metabolic Disease | HER3 antagonists HER4 agonists NRG1 inhibitors | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Salubris Biotherapeutics, Inc. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Shenzhen Salubris Pharmaceuticals Co., Ltd.) | - | - | detail > | |
| KTN-3379 | KTN-3379 | Monoclonal antibody | Neoplasms Endocrinology and Metabolic Disease Other Diseases | HER3 antagonists | MedImmune LLC | MedImmune LLC | Phase 2 | - | - | - | - | - | - | - | - | - | KTN-3379 | - | - | detail > | |
| Kahalalide F | Kahalalide F | Synthetic peptide | Neoplasms | HER3 antagonists | Vrije Universiteit Amsterdam | Vrije Universiteit Amsterdam | Phase 2 | - | - | - | - | - | - | - | - | - | Kahalalide F | - | - | detail > | |
| YL-202 | YL-202 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | HER3 antagonists TOP1 inhibitors | Suzhou Medilink Therapeutics Ltd. | BioNTech SE BioNTech (Shanghai) Pharmaceuticals Co., Ltd. Suzhou Medilink Therapeutics Ltd. Medilink Therapeutics | Phase 2 | Phase 2 | - | - | - | - | - | Cleavable linker | YL0010014 | 8 | YL-202 | IgG1 - nd | - | detail > | |
| SHR-A2009 | SHR-A2009 | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Respiratory Diseases | HER3 antagonists TOP1 inhibitors | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Suzhou Suncadia Biopharmaceuticals Co., Ltd. Shandong Suncadia Medicine Co., Ltd. Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Phase 3 | Phase 3 | - | - | - | Fast Track（United States） | - | Protease cleavable linker | 9106-IM-2 | 4 | SHR-A2009 | - | - | detail > |
Total 141 data
1
2
3
4
5
6
...
14
15
